Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients

被引：2

作者：

Ferrucci, Silvia ^{[1
]}

Tavecchio, Simona ^{[1
]}

Maronese, Carlo Alberto ^{[1
,2
]}

Balato, Anna

Di Brizzi, Eugenia Veronica ^{[3
]}

Ortoncelli, Michela ^{[4
]}

Ribero, Simone ^{[4
]}

Girolomoni, Giampiero ^{[5
]}

Maurelli, Martina ^{[5
]}

Fortina, Anna Belloni ^{[6
]}

Caroppo, Francesca ^{[6
]}

Naldi, Luigi ^{[7
,8
]}

Pezzolo, Elena ^{[8
]}

Nettis, Eustachio ^{[9
]}

Pugliese, Francesco ^{[9
]}

Stingeni, Luca ^{[10
]}

Hansel, Katharina ^{[10
]}

Rubegni, Giovanni ^{[11
]}

Calabrese, Laura ^{[12
]}

Russo, Filomena ^{[13
]}

Gola, Massimo ^{[14
]}

Magnaterra, Elisabetta ^{[14
]}

Rongioletti, Franco ^{[15
]}

Mercuri, Santo Raffaele ^{[15
]}

Paolino, Giovanni ^{[15
]}

Savoia, Paola ^{[16
,17
]}

Veronese, Federica ^{[17
]}

Foti, Caterina ^{[18
]}

Ambrogio, Francesca ^{[19
]}

Scalvenzi, Massimiliano ^{[20
]}

Napolitano, Maddalena

Patruno, Cataldo ^{[21
]}

Dastoli, Stefano ^{[21
]}

Corazza, Monica ^{[22
]}

Borghi, Alessandro ^{[22
]}

Calzavara-Pinton, Pier Giacomo ^{[23
]}

Rossi, Mariateresa ^{[23
]}

Offidani, Annamaria ^{[24
]}

Radi, Giulia ^{[24
]}

Bonzano, Laura ^{[25
]}

Ferreli, Caterina ^{[26
]}

Piras, Viviana ^{[26
]}

Satta, Rosanna ^{[27
]}

Sucato, Federica ^{[27
]}

Malagoli, Piergiorgio ^{[28
]}

Gaiani, Francesca ^{[28
]}

Micali, Giuseppe ^{[29
]}

Musumeci, Maria Letizia ^{[29
]}

Fargnoli, Maria Concetta ^{[30
]}

Esposito, Maria ^{[31
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[2] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[3] Univ Campania Luigi Vanvitelli, Dermatol Unit, Naples, Italy

[4] Univ Turin, Med Sci Dept, Dermatol Clin, Turin, Italy

[5] Univ Verona, Dept Med, Sect Dermatol, Verona, Italy

[6] Univ Padua, Dept Women & Children Hlth, Padua, Italy

[7] Italian Grp Epidemiol Res Dermatol, Study Ctr, Bergamo, Italy

[8] San Bortolo Hosp Vicenza, Dept Dermatol, Vicenza, Italy

[9] Univ Bari, Sch & Chair Allergol & Clin Immunol, Dept Emergency & Organ Transplantat, Bari, Italy

[10] Univ Perugia, Dept Med, Sect Dermatol, Perugia, Italy

[11] Univ Siena, Dept Ophthalmol, Siena, Italy

[12] Univ Siena, Dept Med Sci Surg & Neurosci, Sect Dermatol, Siena, Italy

[13] IDI IRCCS, Ist Dermopat Immacolata, Rome, Italy

[14] Azienda Sanit & Univ Florence, Piero Palagi Hosp, Sect Dermatol, Viale Michelangiolo, Florence, Italy

[15] IRCCS San Raffaele Hosp, Dermatol Clin, Milan, Italy

[16] Univ Piemonte Orientale, Dept Hlth Sci, Novara, Italy

[17] AOU Maggiore della Carita Novara, Novara, Italy

[18] Univ Bari, Dept Dermatol, Dipartimento Sci Biomed & Oncol Umana, Bari, Puglia, Italy

[19] Univ Bari, Dept Precis & Regenerat Med & Ionian Area DiMePRe, Sect Dermatol & Venereol, Bari, Italy

[20] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[21] Magna Graecia Univ Catanzaro, Catanzaro, Calabria, Italy

[22] Univ Ferrara, Dept Med Sci, Sect Dermatol, Ferrara, Emilia Romagna, Italy

[23] Univ Brescia, Dermatol Dept, Brescia, Italy

[24] Univ Politecn Marche, Dept Clin & Surg Specialties, Fac Med & Chirurg, Ancona, Marche, Italy

[25] AUSL Modena, Allergol Serv, Modena, Italy

[26] Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Dermatol, Cagliari, Italy

[27] Univ Sassari, Dept Med Surg & Expt Sci, Dermatol Unit, Sassari, Italy

[28] Ist Policlin San Donato, Milan, Italy

[29] Univ Catania, Catania, Italy

[30] Univ Aquila, Dept Dermatol, Laquila, Italy

[31] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[32] Univ Rome Sapienza, Dermatol Unit, Rome, Italy

[33] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2024年 / 49卷 / 12期

关键词：

EUROPEAN GUIDELINES; ADULTS; MANAGEMENT; PLACEBO;

D O I：

10.1093/ced/llae208

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background The efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long-term treatment outcomes is currently available to inform clinical decisions. Objectives To describe the long-term effectiveness and safety of dupilumab up to 48 months in patients with moderate-to-severe AD. Methods A multicentre, retrospective, dynamic cohort study was conducted to assess long-term effectiveness and safety of dupilumab in patients with moderate-to-severe AD in a real-world setting. Predictors of minimal disease activity (MDA) optimal treatment target criteria [defined as the simultaneous achievement of a 90% reduction in Eczema Area and Severity Index score, itch-numeric rating scale (NRS) score <= 1, sleep-NRS score <= 1 and Dermatology Life Quality Index <= 1] were investigated. Results In total, 2576 patients were enrolled from June 2018 to July 2022. MDA optimal treatment target criteria were achieved by 506/2309 (21.9%), 769/1959 (39.3%), 628/1247 (50.4%), 330/596 (55.4%) and 58/106 (54.7%) of those that reached 4, 12, 24, 36 and 48 months of follow-up, respectively. Logistic regression revealed a negative effect on MDA achievement for conjunctivitis and food allergy at all timepoints. Adverse events (AEs) were mild and were observed in 373/2364 (15.8%), 166/2066 (8.0%), 83/1291 (6.4%), 27/601 (4.5%) and 5/110 (4.5%) of those that reached 4, 12, 24, 36 and 48 months of follow-up. Conjunctivitis was the most frequently reported AE during the available follow-up. AEs led to treatment discontinuation in < 1% of patients during the evaluated time periods. Conclusions The high long-term effectiveness and safety of dupilumab were confirmed in this dynamic cohort of patients with moderate-to-severe AD, regardless of clinical phenotype and course (persisting or relapsing) at baseline. Further research will be needed to investigate the effect of T helper cell 2 comorbidities and disease duration on the response to dupilumab and other newer therapeutics for AD.

引用

页码：1561 / 1572

页数：12

共 50 条

[21] A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world
Dong Hyek Jang
Seok Jae Heo
Hyung Don Kook
Dong Heon Lee
Hye Jung Jung
Mi Yeon Park
Jiyoung Ahn
Scientific Reports, 11
[22] A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis
Napolitano, Maddalena
Fabbrocini, Gabriella
Potestio, Luca
Fontanella, Giuseppina
Picone, Vincenzo
Bennardo, Luigi
Scalvenzi, Massimiliano
Patruno, Cataldo
DERMATOLOGIC THERAPY, 2022, 35 (08)
[23] Efficacy and safety of long-term treatment with dupilumab for moderate to severe atopic dermatitis
Ikeda, M.
Uehara, H.
Tsuge, M.
ALLERGY, 2019, 74 : 182 - 182
[24] A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world
Jang, Dong Hyek
Heo, Seok Jae
Kook, Hyung Don
Lee, Dong Heon
Jung, Hye Jung
Park, Mi Yeon
Ahn, Jiyoung
SCIENTIFIC REPORTS, 2021, 11 (01)
[25] LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Wollenberg, Andreas
Paller, Amy S.
Bewley, Anthony
Cork, Michael
Hong, Chih-Ho
Soong, Weily
Oland, Christian Bjerregard
Taveira, Christian Moreira
Gjerum, Le
Blauvelt, Andrew
ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 54 - 54
[26] Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity
Dupuis, Josephine
Tauber, Marie
Mahe, Emmanuel
Jachiet, Marie
Soria, Angele
Tetart, Florence
Puzenat, Eve
Pasteur, Justine
Raison-Peyron, Nadia
Giordano-Labadie, Francoise
Droitcourt, Catherine
Leleu, Camille
Nosbaum, Audrey
Aubert, Helene
Moigne, Marie L. E.
Bernier, Claire
Barbarot, Sebastien
Ezzedine, Khaled
Diaz, Emmanuelle
Hubiche, Thomas
Faiz, Sarah
Azib, Selma
Dezoteux, Frederic
Chosidow, Olivier
Staumont-Salle, Delphine
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (02) : e174 - e178
[27] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
Cork, M. J.
Eichenfield, L. F.
Blauvelt, A.
Rosmarin, D.
Hussain, I.
Davis, J. D.
Li, M.
Zhang, Q.
Gadkari, A.
Eckert, L.
Kamal, M. A.
Bansal, A.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
[28] Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
Jang, Dong Hyek
Heo, Seok Jae
Jung, Hye Jung
Park, Mi Yeon
Seo, Seong Jun
Ahn, Jiyoung
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 12
[29] A 52 WEEKS RETROSPECTIVE STUDY OF DUPILUMAB TREATMENT FOR MODERATE TO SEVERE ATOPIC DERMATITIS IN KOREA: LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN REAL WORLD PRACTICE
Ahn, Jiyoung
Jang, Dong Hyek
Heo, Seok Jae
Lee, Dong Heon
Jung, Hye Jung
Park, Mi Yeon
Seo, Seoung Jun
ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 13 - 13
[30] Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab
Cioppa, Vittoria
Lazzeri, Laura
Carraro, Andrea
De Piano, Ernesto
Falcinelli, Francesca
Galluzzo, Marco
Pallotta, Sabatino
De Pita, Ornella
Russo, Filomena
DERMATITIS, 2024, 35

← 1 2 3 4 5 →